PubRank

James D Griffin

Author PubWeight™ 187.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005 17.41
2 A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003 11.17
3 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 8.26
4 Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 7.99
5 The roles of FLT3 in hematopoiesis and leukemia. Blood 2002 6.14
6 Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol 2003 4.43
7 Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010 4.00
8 Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2004 3.84
9 Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003 3.75
10 PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 2007 3.54
11 The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005 3.48
12 c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003 3.39
13 Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007 3.36
14 High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008 3.30
15 Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007 3.23
16 Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002 3.09
17 PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. Cancer Cell 2003 2.70
18 Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A 2009 2.54
19 Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 2005 2.49
20 Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 2002 2.42
21 t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003 2.30
22 The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011 2.23
23 The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. Blood 2005 2.14
24 Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood 2007 1.85
25 Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2006 1.83
26 Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci U S A 2004 1.82
27 Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2004 1.81
28 Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol Cell Biol 2002 1.81
29 PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004 1.81
30 Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res 2004 1.79
31 The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis. Genes Dev 2006 1.79
32 BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002 1.62
33 AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005 1.61
34 Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005 1.58
35 The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 2008 1.55
36 Role of FLT3 in leukemia. Curr Opin Hematol 2002 1.52
37 Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J 2005 1.48
38 FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML. Drug Resist Updat 2009 1.47
39 NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML. Blood 2014 1.44
40 Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer 2010 1.33
41 The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem 2007 1.33
42 Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. Blood 2010 1.32
43 FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene 2005 1.32
44 Activated Jak2 with the V617F point mutation promotes G1/S phase transition. J Biol Chem 2006 1.31
45 Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004 1.27
46 Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 2003 1.26
47 Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev Med Chem 2004 1.26
48 A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. Mol Cell Proteomics 2009 1.25
49 Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. Mol Cancer Ther 2008 1.23
50 The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2003 1.22
51 NPM-ALK fusion kinase of anaplastic large-cell lymphoma regulates survival and proliferative signaling through modulation of FOXO3a. Blood 2004 1.21
52 Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther 2007 1.18
53 Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene 2002 1.17
54 FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 2004 1.17
55 Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2003 1.16
56 BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair. Blood 2009 1.13
57 Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology 2006 1.09
58 Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. Blood 2008 1.09
59 After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood 2004 1.09
60 Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol 2013 1.08
61 FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 2005 1.05
62 The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer 2012 1.05
63 The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 2002 1.04
64 A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration. J Biol Chem 2002 1.03
65 Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol 2004 1.02
66 Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol 2013 1.01
67 Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. Blood 2008 1.01
68 Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Curr Med Res Opin 2010 0.99
69 Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood 2002 0.98
70 A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets. Clin Cancer Res 2013 0.95
71 The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development. Blood 2007 0.95
72 Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells. FASEB J 2005 0.93
73 Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 2010 0.90
74 Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin. J Clin Invest 2004 0.90
75 The mastermind-like 1 (MAML1) co-activator regulates constitutive NF-kappaB signaling and cell survival. J Biol Chem 2010 0.90
76 Discovery of a selective irreversible BMX inhibitor for prostate cancer. ACS Chem Biol 2013 0.89
77 Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol 2014 0.88
78 Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells. PLoS One 2013 0.88
79 Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison. Genes Cancer 2010 0.87
80 Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene 2002 0.87
81 The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell 2016 0.87
82 Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood 2004 0.85
83 Following the cytokine signaling pathway to leukemogenesis: a chronology. J Clin Invest 2008 0.84
84 Discovery and characterization of novel mutant FLT3 kinase inhibitors. Mol Cancer Ther 2010 0.84
85 Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 2003 0.84
86 Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS One 2011 0.84
87 Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene. Gene 2004 0.83
88 A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin 2012 0.82
89 JAK2 gets histone H3 rolling. Cancer Cell 2009 0.80
90 A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples. Blood 2006 0.80
91 Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv Exp Med Biol 2003 0.79
92 Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target? Curr Cancer Drug Targets 2013 0.79
93 Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner. Genes Cancer 2010 0.79
94 An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit. Bioorg Med Chem Lett 2012 0.78
95 Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways. Leuk Lymphoma 2003 0.78
96 Interaction maps for kinase inhibitors. Nat Biotechnol 2005 0.77
97 Development of 'DFG-out' inhibitors of gatekeeper mutant kinases. Bioorg Med Chem Lett 2012 0.77
98 Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies. Arch Toxicol 2014 0.76
99 The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors. Int J Hematol 2004 0.75